Incyte Genomics Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for INCY, updated each market day.
INCY AI Sentiment
AI sees no strong directional signal for Incyte Genomics Inc stock over the next 10 market days.
Prediction date: Sept. 21, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Incyte Genomics Inc
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Sector
Exchange
Market Cap
$25,868,286,344
Cap Tier
Employees
2,844
Headquarters
WILMINGTON, DE
Listed Since
Nov. 3, 1993
Website
INCY Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
INCY Volatility
Incyte Genomics Inc has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
